Recent

% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

  • wildbullus wildbullus May 17, 2013 6:37 PM Flag

    z944 P1 MAD completed in late 2012

    Z944 Presented at the American Pain Society 2013 Annual Meeting

    Z944 is a novel, oral, state-dependent, selective T-type calcium channel blocker that has demonstrated preclinical efficacy in multiple inflammatory pain models. T-type calcium channels have been recognized as key targets for therapeutic intervention in a broad range of cell functions and have been implicated in pain signaling. Zalicus completed Phase 1 single and multiple ascending dose clinical studies evaluating the safety and tolerability of Z944 in late 2012 and plans to continue further clinical development during 2013.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ZLCS
0.00(0.00%)